CLINICAL CANCER RESEARCH

CLINICAL CANCER RESEARCH Journal

publication venue for

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. 30:63-73. 2024
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. 29:4596-4605. 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. 29:1047-1055. 2023
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. 28:4186-4193. 2022
Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. 26:3481-3490. 2020
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. 25:5584-5594. 2019
RADIANCE: An open-label, nonrandomized, prospective biomarker study to assess analytic concordance between noninvasive testing and tissue testing for EGFR T790M mutation detection in patients with non-small cell lung cancer 2018
ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). 2018
ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). 2018
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. 23:2186-2194. 2017
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. 21:4321-4326. 2015
CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells. 21:2075-2083. 2015
A comparison of patient outcomes in advanced ovarian cancer: Assay-informed vs. empirically treated 2013
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer. 19:3068-3077. 2013
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. 19:2629-2636. 2013
A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors. 19:268-278. 2013
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission. 18:6509-6518. 2012
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors. 17:7754-7764. 2011
Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types. 16:4864-4875. 2010
DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma. 16:1997-2008. 2010
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. 15:6277-6283. 2009
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. 15:2552-2558. 2009
Antibodies to the epidermal growth factor receptor in non-small cell lung cancer: Current status of matuzumab and panitumumab. 13:4597S-4601S. 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge conference 2007
A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. 13:2091-2099. 2007
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. 11:5045S-5050S. 2005
An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. 11:3697-3704. 2005
Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms. 10:4210S-4214S. 2004
Novel agents in the treatment of lung cancer: Conference summary statement 2004
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: Toxicity and immunological effects. 9:1354-1360. 2003
Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. 7:3491-3494. 2001
Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. 4:1943-1948. 1998
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. 4:1279-1285. 1998

category

ONCOLOGY Web of Science Category

International Standard Serial Number (ISSN)

1078-0432

Electronic International Standard Serial Number (EISSN)

1557-3265

journal abbreviation

CLIN CANCER RES